The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| STOK | +143.04% | -21.75% | -4.78% | +24% |
| S&P | +19.89% | +109.18% | +15.89% | +134% |
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
This small-cap biotech might be a hidden gem.
The company's shares fell after it released early trial results on its lead therapy.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.82M | 186.0% |
| Gross Profit | $12.76M | 242.9% |
| Gross Margin | 92.34% | 15.3% |
| Market Cap | $619.67M | -12.0% |
| Market Cap / Employee | $4.84M | 0.0% |
| Employees | 128 | 16.4% |
| Net Income | -$23.48M | 8.6% |
| EBITDA | -$26.24M | 7.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $101.55M | -47.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.26M | -64.7% |
| Short Term Debt | $2.30M | 0.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 15.16% | 51.8% |
| Return On Invested Capital | -42.61% | -4.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$25.58M | -46.0% |
| Operating Free Cash Flow | -$25.42M | -45.5% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 8.45 | 13.43 | - | ||
| Price to Book | 2.80 | 2.52 | 1.57 | 1.77 | -60.45% |
| Price to Sales | 41.36 | 17.21 | 2.07 | 3.31 | -93.33% |
| Price to Tangible Book Value | 2.80 | 2.52 | 1.57 | 1.77 | -60.45% |
| Price to Free Cash Flow TTM | 5.71 | 10.83 | - | ||
| Enterprise Value to EBITDA | -15.87 | -33.22 | 0.37 | -15.93 | -5.74% |
| Free Cash Flow Yield | 17.5% | 9.2% | - | ||
| Return on Equity | -52.1% | -45.8% | 20.5% | 18.2% | -137.98% |
| Total Debt | $5.31M | $4.77M | $4.21M | $3.55M | -39.07% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
